You are here: Industry Insights > INOVIO

News List

INOVIO, Advaccine Enter Exclusive COVID-19 DNA Vax Pact contractpharma
January 05, 2021
Partnership adds Asian manufacturing resource to INOVIO's global manufacturing consortium for INO-4800.
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine prnasia
December 25, 2020
INOVIO announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine, an open access clinical journal published by The Lancet.
INOVIO Doses First Subject in INO-4800 Trial to Prevent COVID-19 americanpharmaceuticalreview
December 24, 2020
INOVIO has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy).
INOVIO to Develop dMAb COVID Treatments under DARPA Grant contractpharma
December 16, 2020
$37.6 million grant will leverage AstraZeneca's monoclonal antibody and INOVIO's dMAb technologies in the fight against COVID-19.
Inovio initiates dosing in Phase II segment of Covid-19 therapy trial pharmaceutical-technology
December 09, 2020
Biotechnology firm Inovio has dosed the first participant in a Phase II segment of its Phase II / III INovio INO-4800 Vaccine Trial for Efficacy (INNOVATE) trial analysing its Covid-19 vaccine candidate, INO-4800.
INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19 prnasia
December 08, 2020
INOVIO announced it has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy).
Keneka Eurogentec Joins Inovio’s Global Mfg. Consortium contractpharma
December 07, 2020
Inovio, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, has executed an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation ...
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A. prnasia
December 04, 2020
INOVIO announced the execution of an agreement with Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, for Eurogentec to manufacture INOVIO's COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales.
Inovio signs deal with Japan’s Kaneka for COVID-19 vaccine manufacturing expresspharma
December 04, 2020
Inovio has also signed manufacturing deals with medical device maker Thermo Fisher Scientific among others.
INOVIO COVID-19 vaccine trials on partial hold after additional queries from US FDA expresspharma
October 10, 2020
Working to address the FDA's questions and plans to respond in October, informed the company.

Previous page 1 2 3 4 5 Next page